Yes, I did that as part of my pre-flight check list and it does look like it could add a few dollars but I started a short anyway- at 79.94, a little early it turns out. I enter in up to three stages and that was stage one.
I think it is being goosed along more than the news warrants, aided by the OS that is tightly held.
Trial 2 results for efficacy only were apparently favorable but it's no slam dunk and a long way to possible approval. This cancer drug candidate, "Neratinib" was licensed to PUMA by after Pfizer's own Trial 2 of elicited terrible side effects- worse than chemo.
Conceivably a winner in the long run but with bios the odds are always against that.
Anyway, 88% in two days seems stretched, and an RSI at 86 says overbought.
My second short of PBYI was 35 pts from filling today.
As with any short, it is best to go lightly.
Helping out at my church all weekend- I better get to dreamland!
Have a good weekend, Lee and all!
The shorts who are on here trying to pick up a few scraps would obviously have done better by going long since the stock is now a hair's breadth away from its high. To sit on a short while it goes 7 points underwater also seems like a questionable strategy. (Stops anyone?) The "terrible side effects" story is bogus. The only question is whether neratinib is superior to Herceptin, which has been amply demonstrated in the recent study.
Good morning bob,
Congrats to longs but I wasn't around- I scan for shorts and came upon PBYI.
Re "stops" notice it was the first of a staged entry approach and very light- works for me.
The side effects was garnered from a person very knowledgeable.
GL, I remain short.